Coronavirus: Immunotherapy

(asked on 16th July 2021) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to assist the Medicines and Healthcare products Regulatory Agency to progress the licensing process for the REGEN-COV, Regeneron, monoclonal antibody treatment.


Answered by
Jo Churchill Portrait
Jo Churchill
Minister of State (Department for Work and Pensions)
This question was answered on 27th July 2021

The Medicines and Healthcare products Regulatory Agency’s (MHRA) licensing of therapeutics, including for REGEN-COV, is an independent process. The Therapeutics Taskforce encourages companies seeking approvals for COVID-19 therapeutics to provide the data the MHRA requires to ensure that their products are of acceptable quality, safety and efficacy. Approval can only be determined when the full data has been provided by the manufacturer and assessed by the MHRA.

Reticulating Splines